key: cord-0968877-tvdyc73o
authors: Iaboni, Aled; Jindal, Nina; Betschel, Stephen D.; Song, Christine
title: Second dose mRNA COVID-19 vaccine safety in patients with immediate reactions after the first dose: A case series.
date: 2022-04-14
journal: Journal of Allergy and Clinical Immunology: Global
DOI: 10.1016/j.jacig.2022.03.003
sha: 2a29662a0381ba6aaa11c73ae85a0039f8124da2
doc_id: 968877
cord_uid: tvdyc73o

Background Suspected allergic reactions to the 1st dose of the coronavirus disease 2019 (COVID-19) mRNA vaccines have been reported to be as high as 2%, with anaphylaxis up to 2.5 per 10000 individuals. Anaphylaxis to the 1st dose may be considered a contraindication to administration of the 2nd dose, necessary for optimal protection against severe disease. Many individuals with anaphylactic reactions to the 1st dose still want to receive a 2nd dose. However, there is little published data to support the administration of a 2nd dose safely in this population. Objective The primary outcome for this study was determining the percentage of patients tolerating the 2nd COVID-19 mRNA vaccine dose after an immediate reaction to the 1st dose. Methods This was a retrospective chart review of 47 patients at a Canadian hospital who had immediate, suspected allergic reactions following their 1st COVID-19 mRNA vaccine dose and received a 2nd dose within our allergy clinic. For detailed Methods, please see the Methods section in this article's Online Repository at www.jacionline.org Results 46 of 47 patients tolerated the 2nd dose. 43% of patients developed mild, transient symptoms. There were no patients who developed anaphylaxis or needed epinephrine after the 2nd dose. Conclusion Our case series adds to current evidence that administration of a 2nd COVID-19 mRNA vaccine dose has a good safety profile in patients with a history of immediate reactions after the 1st dose, including those with a history of anaphylaxis to the 1st dose.

occur in up to 2% of individuals. There is emerging evidence that these patients may safely receive their 2 nd 87 dose. Pfizer-BioNTech and Moderna mRNA vaccines have since been given to over 28 million Canadians and 117 are currently approved in patients 12 years of age and older [1] .

Soon after the approval of these vaccines, reports of allergic reactions and anaphylaxis after 1 st doses 119 emerged. A prospective study from the United States showed that acute allergic reactions were as high as 

Immediate was defined as symptom onset <4 hours after vaccine administration. While patients with a history 154 of PEG allergy were not excluded from the study, none met the inclusion criteria. Skin testing to mRNA 155 COVID-19 vaccines or vaccine components was not routinely performed prior to 2 nd dose administration.

Additional methods of the study can be found in the Online Supplement. than antihistamines for treatment. There were no patients who reported biphasic allergic symptoms within 24 169 hours of their 2 nd dose.

Patients who had anaphylaxis after their 1 st dose were somewhat more likely to develop immediate 171 symptoms with the 2 nd dose compared to patients without anaphylaxis (53% vs. 41%). Patients who were 172 given epinephrine after their 1 st dose were also more likely to develop immediate symptoms with the 2 nd dose 173 compared to patients who had not been given epinephrine (50% vs. 41%). There was a higher rate of 174 immediate reactions seen in the premedication group compared to patients who did not receive premedication 175 (50% vs. 22%). No other risk factors were identified for having immediate symptoms after the 2 nd dose.

Asthma and underlying autoimmunity were identified as risk factors for meeting anaphylaxis criteria after 177 the 1st dose. Of the patients who had asthma and autoimmunity, 42% and 33% respectively met clinical 178 criteria for anaphylaxis after their first dose. This was compared to 18% of patients who had neither asthma 179 nor autoimmunity. 

Switching was solely based upon vaccine availability on clinic days.

b Premedication prior to the 2 nd vaccine dose was provided to patients for 3 to 5 days preceding the dose using 308 the following regimens: Montelukast and a non-sedating antihistamine once daily (n=33), and a once daily 

Approved COVID-19 vaccines. Government of Canada